Lansoprazole (Lansoprazole) Patent Expiration, LOE Window & CMS Spending
Lansoprazole (Lansoprazole) by Dexcel Technologies: FDA Orange Book LOE 2036-04-21, 5 AB generics, $60.2M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Dexcel Technologies |
| FDA Application & Pathway | N208025 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2036-04-21 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 5 |
| 2024 CMS Total Public Spend | $60.2M |
| 2024 Medicare Part D Spend | $47.3M |
| 2024 Medicaid Spend | $12.9M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |